A compendium of critical appraisals in Intensive Care Medicine research and related specialties
Standard versus Accelerated Initiation of Renal Replacement Therapy Wald R, Bagshaw S. NEJM July 16 2020 doi:10.1056/NEJMoa2000741 Clinical Question In critically ill patients with severe acute kidney injury, does accelerated initiation of renal replacement therapy compared to standard initiation improve 90 day survival? Background Acute Kidney Injury (AKI) is common in critically ill patients and some case series suggest up […]
Continue reading »
In hospitalised patients with SARS-CoV-2 infection does dexamethasone in additional to usual care, compared to usual care alone, reduce 28-day mortality?
Continue reading »
In patients with gastrointestinal (GI) bleeding does high dose tranexamic acid (TXA) when compared to a placebo reduce mortality from GI bleeding?
Continue reading »
In patients with acute anterior ischaemic stroke, is endovascular thrombectomy alone, compared with endovascular thrombectomy preceded by intravenous alteplase, noninferior with respect to modified Rankin score at 90 days?
Continue reading »
In people who have high-risk or moderate-risk exposure to someone with confirmed COVID-19 infection, does taking hydroxychloroquine following the exposure compared to placebo reduce the incidence of a new illness compatible with COVID-19?
Continue reading »
In critically ill patients with Vitamin D deficiency and a high risk of death, does early enteral replacement of Vitamin D3 compared with placebo improve survival at 90 days?
Continue reading »
In hospitalised adult patients with evidence of lower respiratory tract infection due to COVID-19, is remdesivir superior to placebo in shortening the time to recovery?
Continue reading »
In adult patients with COVID-19, does combined interferon beta-1b, lopinavir-ritonavir, and ribavirin, compared with lopinavir-ritonavir alone, reduce the time to a negative swab result?
Continue reading »
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Wang Y. Lancet; Epub Ahead of Print. doi: https://doi.org/10.1016/S0140-6736(20)31022-9 Clinical Question In patients with severe COVID-19, does intravenous remdesivir, compared with placebo, improve the time to clinical improvement? Background Despite the ongoing research efforts to find a treatment for patients infected with SARS-CoV-2, there are currently no proven […]
Continue reading »
In patients infected with SARS-CoV-2, what is the efficacy and safety of oral lopinavir–ritonavir?
Continue reading »